Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding CDP-1050 as a paradigm for the treatment of heart failure, satisfaction of the medical community and regulatory authorities as to the
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... organized and will present a session on chemical spectroscopic imaging at JASIS 2015 ... exposition is Asia’s largest analytical and scientific instruments show which will be held ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a nationwide consulting ... to announce their ranking as one of the top 5000 companies listed on the ... across the nation. , “It is truly an honor to be recognized as one ...
(Date:8/27/2015)... ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... three and six-month periods ended June 30, 2015. Biorem,s complete second ... www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ... , 2014 , 2015 , 2014 ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... RESEARCH TRIANGLE PARK, N.C. , Aug. 27, ... reports on the decision by FedEx, UPS and ... shipments of certain biological specimens classified as ,select ... expertise and long history of handling these sensitive ... network, knowledge of global transportation regulations, trained and ...
Breaking Biology Technology:U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... Fibrillation, EP Mapping and ... PCI and Additional Complex Procedures, ST. LOUIS, ... announced today that more than 10,000 procedures have ... utilizes,advanced, magnet-guided navigational technology intended to help,electrophysiologists and ...
... is showcasing its,motion management systems at this year,s ... 8-13, 2007, at the Palau de,Congresos de Catalunya ... motion management and patient positioning at the,Elekta booth ... "Holding still for 10 minutes? Bet you ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today provided ... Novartis focused on the development and commercialization of,BCR-ABL ... and drug resistant,Chronic Myelogenous Leukemia (CML). Under ... number of,potential drug candidates, with the anticipated timeline ...
Cached Biology Technology:Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 2Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 3Elekta Brings Intelligent Ways to Manage Motion During Cancer Treatment to ESTRO 2SGX Provides Update on BCR-ABL Collaboration 2SGX Provides Update on BCR-ABL Collaboration 3
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... The December 2009 issue of the Journal ... Christopher Ahern (The University of British Columbia, Vancouver) and ... other K+ channels using in vivo nonsense suppression technology. ... www.jgp.org ). According to Riccardo Olcese (UCLA) in ...
... of New Hampshire assistant professors have received prestigious ... (CAREER) grants. Vaughn Cooper of the department of ... to better understand beneficial mutations in bacteria by ... White of the mechanical engineering department received $400,000 ...
... general rule among mammals that larger males sire more ... Coltman has found a genetic quirk that might make ... Big, heavy males mountain goats shove lightweight Romeos ... males pass their physical attributes and mating success to ...
Cached Biology News:2 UNH faculty receive $1.4M in CAREER grants from NSF 2
... thermostable DNA polymerase obtained by high level ... in E. coli, Concentration: 5U/ul, Applications: Standard ... Scientific, the world leader in serving science. ... the world healthier, cleaner and safer by ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... is a thermostable DNA polymerase derived ... at temperatures above 70°C, it was ... PCR and remains the predominant enzyme ... an intrinsic 5'?3' structure-dependent exonuclease activity, ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Biology Products: